Jeffrey S. Hatfield, President and Chief Executive Officer, Vitae Pharmaceuticals
On behalf of the Biotechnology Industry...
July 26 2012
Dear Majority Leader Reid and Minority Leader McConnell:
On behalf of the Biotechnology Industry Organization (BIO) and its more than 1...
March 16 2012
William D. Waddill, Senior Vice President and Chief Financial Officer OncoMed Pharmaceuticals highlights the importance of capital...
March 6 2012
December 1, 2011
On December 1, BIO submitted written testimony to the Senate Committee on Banking, Housing, and Urban Affairs on the importance of...
December 1 2011
April 7, 2011
Hearing Testimony
Scott Koenig, M.D., PH.D.
Before the House of Representatives Committee on Small Business
Good morning Chairman...
April 7 2011
August 3, 2010
BIO advocated for the recently enacted new Therapeutic Discovery Project Credit program, which was created as a unique opportunity for...
August 3 2010
June 23, 2010
A letter to the House Ways & Means Committee by 54 trade organizations and companies supporting the extension of cellulosic biofuel...
June 23 2010
May 27, 2010
Access to Early Capital
In the United States and globally, commercial development of biotechnology relies on the continuing...
May 27 2010
May 17, 2010
BIO and 34 companies and trade organizations sent a letter to Chairman Levin and Ranking Member Camp, of the House Ways and Means...
May 17 2010
October 14, 2009
Good morning Chairwoman Velázquez, Ranking Member Graves, Members of the Committee, the Staff of the Committee, ladies and...
October 14 2009
April 23, 2009
Good morning Chairman Wu, Ranking Member Smith, Members of the Committee, ladies and gentleman. I am Jim Greenwood, President and CEO of...
April 23 2009
November 15, 2008
BIO urges that changes to FIN46(R) accurately reflect the underlying economics of collaborations.
November 15 2008
September 18, 2008
The letter, signed by approximately 60 patient groups, emphasizes support for restoring eligibility in the SBIR program to venture-backed...
September 18 2008
October 27, 2007
BIO addresses concerns to FASB’s Staff Position on accounting for instrument C and conventional convertible debt.
October 27 2007
July 26, 2005
The letter, signed by over 280 biotech executives, emphasizes support for restoring eligibility in the SBIR program to venture-backed...
July 26 2005
March 25, 2004
March 25 2004
December 10, 2003
December 10 2003
November 4, 2003
To Hector Barreto, Administrator, U.S. Small Business Administration
November 4 2003
October 21, 2003
To Hector Barreto, Administrator, U.S. Small Business Administration
October 21 2003
May 13, 2003
Administrator, U.S. Small Business Administration
May 13 2003